Related Experiment Video
Updated: Apr 11, 2026

04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
Extended-Interval Immunotherapy in Advanced Lung Cancer: A Case Report
Salome Kordzaia1, Lasha Khmaladze1, Elene Dolmazashvili1
1Medical Oncology, Multiprofile Clinic Consilium Medulla Ltd, Tbilisi, GEO.
Cureus
|April 10, 2026
Summary
A modified immunotherapy schedule of every six weeks may stabilize advanced lung adenocarcinoma with brain metastases, potentially reducing toxicities. This approach warrants further clinical trial evaluation for broader applicability.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Case Study
Background:
- Advanced lung adenocarcinoma often presents with metastases, posing treatment challenges.
- Immunotherapy has improved survival but optimal dosing and toxicity management remain critical.
- Immune-related adverse events (irAEs) can limit treatment efficacy and patient quality of life.

